Download Library Categories Annual General MeetingAnnual ReportsCorporate Governance*Corporate PresentationsFact SheetInterim ReportsPodcastsResearch Presentations & PapersWebcasts Year None20192018201720162015201420132012201120102009200820072006200520042003200220012000 Document Type 37th Annual JP Morgan Healthcare Conference - January 2019 37th Annual JP Morgan Healthcare Conference - January 2019 Articles of association dated December 10, 2018 – English Articles of association dated December 10, 2018 – English Genmab 2018 ASH Data Review Genmab 2018 ASH Data Review Jefferies European Healthcare Conference - November 2018 Jefferies European Healthcare Conference - November 2018 Genmab Third Quarter 2018 Results Podcast Genmab Third Quarter 2018 Results Podcast Investor Fact Sheet Investor Fact Sheet Genmab Q3 2018 Results Presentation Genmab Q3 2018 Results Presentation Interim Report for the First Nine Months of 2018 Interim Report for the First Nine Months of 2018 Genmab's 2018 Capital Markets Day - September 26, 2018 Genmab's 2018 Capital Markets Day - September 26, 2018 Genmab Investor Presentation - September 12, 2018 Genmab Investor Presentation - September 12, 2018 Investor Presentation, August 2018 Investor Presentation, August 2018 Genmab 2018 Second Quarter Results Presentation Genmab 2018 Second Quarter Results Presentation Interim Report for the First Half 2018 Interim Report for the First Half 2018 Genmab Second Quarter 2018 Results Podcast Genmab Second Quarter 2018 Results Podcast Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (greater than or equal to 75 Years of age) Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplantation (ALCYONE) - EHA Oral Presentation - June 2018 (Cavo) Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (greater than or equal to 75 Years of age) Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplantation (ALCYONE) - EHA Oral Presentation - June 2018 (Cavo) Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Oral Presentation - June 2018 (Casneuf) Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Oral Presentation - June 2018 (Casneuf) Articles of Association - June 7 2018 - English Articles of Association - June 7 2018 - English Subcutaneous Daratumumab (DARA SC) + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA - EHA Poster Presentation - June 2018 (Merlini) Subcutaneous Daratumumab (DARA SC) + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA - EHA Poster Presentation - June 2018 (Merlini) Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) - EHA Poster Presentation - June 2018 (San-Miguel) Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) - EHA Poster Presentation - June 2018 (San-Miguel) Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) - EHA Poser Presentation - June 2018 (Cavo) Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) - EHA Poser Presentation - June 2018 (Cavo) Daratumumab, Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide-refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 - EHA Poster Presentation - June 2018 (Moreau) Daratumumab, Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide-refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 - EHA Poster Presentation - June 2018 (Moreau) Genmab Investor Presentation - June 2018 Genmab Investor Presentation - June 2018 Phase 3 study of subcutaneous Daratumumab vs active monitoring in patients with high-risk Smoldering Multiple Myeloma: AQUILA - ASCO poster - June 2018 (Rajkumar) Phase 3 study of subcutaneous Daratumumab vs active monitoring in patients with high-risk Smoldering Multiple Myeloma: AQUILA - ASCO poster - June 2018 (Rajkumar) Daratumumab plus Bortezomib-Melphalan-Prednisone in elderly (greater than or equal to 75 y) patients with newly diagnosed Multiple Myeloma ineligible for transplantation (ALCYONE) (MMY3007) - ASCO poster - June 2018 (Cavo) Daratumumab plus Bortezomib-Melphalan-Prednisone in elderly (greater than or equal to 75 y) patients with newly diagnosed Multiple Myeloma ineligible for transplantation (ALCYONE) (MMY3007) - ASCO poster - June 2018 (Cavo) Phase 3 study of subcutaneous vs intravenous DARA administration in pts with relapsed or refractory Multiple Myeloma: COLUMBA (MMY3012) - ASCO poster - June 2018 (Usmani) Phase 3 study of subcutaneous vs intravenous DARA administration in pts with relapsed or refractory Multiple Myeloma: COLUMBA (MMY3012) - ASCO poster - June 2018 (Usmani) Phase 2, multicenter trial of tisotumab vedotin in previously treated, recurrent or metastatic cervical cancer - ASCO poster - June 2018 (Coleman) Phase 2, multicenter trial of tisotumab vedotin in previously treated, recurrent or metastatic cervical cancer - ASCO poster - June 2018 (Coleman) Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »